FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. Described is the plasmid pVBL-RBDdelta containing a nucleotide sequence encoding the SARS-CoV-2-line B.1.617.2 RBD protein and providing expression of this RBD protein in mammalian cells and further purification by affinity chromatography. The resulting RBD protein is intended for the direct production of a vaccine preparation against SARS-CoV-2-line B.1.617.2.
EFFECT: invention expands the arsenal of agents for the treatment of coronavirus infection.
1 cl, 1 dwg, 1 tbl, 4 ex
Authors
Dates
2022-05-26—Published
2021-12-13—Filed